Statement: febrile neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5/6 of patients
Primary_evidence: Adverse Events 1:   Total: 11/56 (19.64%)   Febrile Neutropenia * 3/56 (5.36%)   Neutropenia * 1/56 (1.79%)   Pancytopenia * 1/56 (1.79%)   Atrial Fibrillation * 1/56 (1.79%)   Coronary Artery Disease * 1/56 (1.79%)   Constipation * 1/56 (1.79%)   Chest Pain * 1/56 (1.79%)   Non-Cardiac Chest Pain * 1/56 (1.79%)   Edema due to Cardiac Disease * 1/56 (1.79%)   Cellulitis * 1/56 (1.79%)